Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: Binding studies and crystal structure

Journal of Biological Chemistry

Volumn 287, Issue 19, 2012, Pages 15935-15946

  Batra, Jyotica ^a   Robinson, Jessica ^a,c   Soares, Alexei S ^b   Fields, Alan P ^a   Radisky, Derek C ^a   Radisky, Evette S ^a  

^a MAYO CLINIC   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING INTERFACE; BINDING STUDIES; CATALYTIC DOMAINS; DIFFERENTIAL BINDING; INHIBITION CONSTANTS; MATRIX METALLOPROTEINASES; METALLOPROTEINASES; MOLECULAR REPLACEMENTS; OVER-EXPRESSION; PROTEIN DATA BANK; SKELETAL DEVELOPMENT; STRUCTURAL INFORMATION; THERAPEUTIC APPLICATION; TISSUE INHIBITOR; TUMOR PROGRESSIONS; TUMORIGENESIS; VASCULAR REMODELING; WOUND HEALING; X RAY CRYSTAL STRUCTURES;

EQUILIBRIUM CONSTANTS; TISSUE;

BLOOD VESSELS;

STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GENE SEQUENCE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

BINDING SITES; BINDING, COMPETITIVE; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; KINETICS; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 3; MODELS, MOLECULAR; MUTATION; PROTEIN STRUCTURE, TERTIARY; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84860868139     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.341156     Document Type: Article

References (87)

1. Murphy, G., and Nagase, H. (2008) Progress in matrix metalloproteinase research. Mol. Aspects Med. 29, 290-308
2. Radisky, E. S., and Radisky, D. C. (2010) Matrix metalloproteinase- induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15, 201-212
3. Nagase, H., and Brew, K. (2002) Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res. 4, S51-S61
4. Nagase, H., Visse, R., and Murphy, G. (2006) Cardiovasc. Res. 69, 562-573
5. Nicholson, R., Murphy, G., and Breathnach, R. (1989) Human and rat malignant tumor-associated mRNAs encode stromelysin-like metalloproteinases. Biochemistry 28, 5195-5203 (Pubitemid 19162769)
6. Nakamura, H., Fujii, Y., Ohuchi, E., Yamamoto, E., and Okada, Y. (1998) Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur. J. Biochem. 253, 67-75
7. Bord, S., Horner, A., Hembry, R. M., and Compston, J. E. (1998) Stromelysin- 1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone. Potential roles in skeletal development. Bone 23, 7-12 (Pubitemid 28327495)
8. Saarialho-Kere, U. K., Pentland, A. P., Birkedal-Hansen, H., Parks, W. C., and Welgus, H. G. (1994) Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. The J. Clin. Invest. 94, 79-88 (Pubitemid 24218079)
9. Windsor, L. J., Grenett, H., Birkedal-Hansen, B., Bodden, M. K., Engler, J. A., and Birkedal-Hansen, H. (1993) Cell type-specific regulation of SL-1 and SL-2 genes. Induction of the SL-2 gene but not the SL-1 gene by human keratinocytes in response to cytokines and phorbolesters. J. Biol. Chem. 268, 17341-17347 (Pubitemid 23236972)
10. Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., and Olson, E. N. (2006) Histone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. Cell 126, 321-334 (Pubitemid 44092958)
11. Rodriguez, J. A., Orbe, J., Martinez de Lizarrondo, S., Calvayrac, O., Rodriguez, C., Martinez-Gonzalez, J., and Paramo, J. A. (2008) Metalloproteinases and atherothrombosis. MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front. Biosci. 13, 2916-2921 (Pubitemid 351589208)
12. Gomis-Ruth, F. X., Maskos, K., Betz, M., Bergner, A., Huber, R., Suzuki, K., Yoshida, N., Nagase, H., Brew, K., Bourenkov, G. P., Bartunik, H., and Bode, W. (1997) Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 389, 77-81 (Pubitemid 27387694)
13. Baker, A. H., Edwards, D. R., and Murphy, G. (2002) Metalloproteinase inhibitors. Biological actions and therapeutic opportunities. J. Cell Sci. 115, 3719-3727 (Pubitemid 35203598)
14. Coussens, L. M., Fingleton, B., and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer. Trials and tribulations. Science 295, 2387-2392
15. Turk, B. (2006) Targeting proteases. Successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799
16. Burrage, P. S., and Brinckerhoff, C. E. (2007) Molecular targets in osteoarthritis. Metalloproteinases and their inhibitors. Curr. Drug Targets 8, 293-303
17. Fingleton, B. (2008) MMPs as therapeutic targets. Still a viable option? Semin. Cell Dev. Biol. 19, 61-68
18. Overall, C. M., and Kleifeld, O. (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J. Cancer 94, 941-946
19. Hu, J., Van den Steen, P. E., Sang, Q. X., and Opdenakker, G. (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6, 480-498 (Pubitemid 47064570)
20. Van Themsche, C., Alain, T., Kossakowska, A. E., Urbanski, S., Potworowski, E. F., and St-Pierre, Y. (2004) Stromelysin-2 (matrix metalloproteinase 10) is inducible in lymphoma cells and accelerates the growth of lymphoid tumors in vivo. J. Immunol. 173, 3605-3611 (Pubitemid 39280719)
21. Gill, J. H., Kirwan, I. G., Seargent, J. M., Martin, S. W., Tijani, S., Anikin, V. A., Mearns, A. J., Bibby, M. C., Anthoney, A., and Loadman, P. M. (2004) MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 6, 777-785 (Pubitemid 40041496)
22. Frederick, L. A., Matthews, J. A., Jamieson, L., Justilien, V., Thompson, E. A., Radisky, D. C., and Fields, A. P. (2008) Matrix metalloproteinase-10 is a critical effector of protein kinase Ciota-Par6α-mediated lung cancer. Oncogene 27, 4841-4853
23. Regala, R. P., Justilien, V., Walsh, M. P., Weems, C., Khoor, A., Murray, N. R., and Fields, A. P. (2011) Matrix metalloproteinase-10 promotes Kras-mediated bronchio-alveolar stem cell expansion and lung cancer formation. PloS One 6, e26439
24. Deraz, E. M., Kudo, Y., Yoshida, M., Obayashi, M., Tsunematsu, T., Tani, H., Siriwardena, S. B., Keikhaee, M. R., Qi, G., Iizuka, S., Ogawa, I., Campisi, G., Lo Muzio, L., Abiko, Y., Kikuchi, A., and Takata, T. (2011) MMP-10/stromelysin-2 promotes invasion of head and neck cancer. PloS One 6, e25438
25. Crombez, L., Marques, B., Lenormand, J. L., Mouz, N., Polack, B., Trocme, C., and Toussaint, B. (2005) High level production of secreted proteins. Example of the human tissue inhibitor of metalloproteinases 1. Biochem. Biophys. Res. Commun. 337, 908-915 (Pubitemid 41447000)
26. Lee, J. E., Fusco, M. L., and Saphire, E. O. (2009) An efficient platform for screening expression and crystallization of glycoproteins produced in human cells. Nat. Protoc. 4, 592-604
27. Suzuki, K., Kan, C. C., Hung, W., Gehring, M. R., Brew, K., and Nagase, H. (1998) Expression of human pro-matrix metalloproteinase 3 that lacks the N-terminal 34 residues in Escherichia coli. Autoactivation and interaction with tissue inhibitor of metalloproteinase 1 (TIMP-1). Biol. Chem. 379, 185-191 (Pubitemid 28075978)
28. Marcy, A. I., Eiberger, L. L., Harrison, R., Chan, H. K., Hutchinson, N. I., Hagmann, W. K., Cameron, P. M., Boulton, D. A., and Hermes, J. D. (1991) Human fibroblast stromelysin catalytic domain. Expression, purification, and characterization of a C-terminally truncated form. Biochemistry 30, 6476-6483
29. Nagase, H., Enghild, J. J., Suzuki, K., and Salvesen, G. (1990) Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 29, 5783-5789 (Pubitemid 20192450)
30. Suzuki, K., Enghild, J. J., Morodomi, T., Salvesen, G., and Nagase, H. (1990) Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 29, 10261-10270
31. Nagase, H. (1995) Human stromelysins 1 and 2. Methods Enzymol. 248, 449-470
32. Weingarten, H., Martin, R., and Feder, J. (1985) Synthetic substrates of vertebrate collagenase. Biochemistry 24, 6730-6734 (Pubitemid 16207157)
33. Weingarten, H., and Feder, J. (1985) Spectrophotometric assay for vertebrate collagenase. Anal. Biochem. 147, 437-440 (Pubitemid 15005881)
34. Murphy, G., and Willenbrock, F. (1995) Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 248, 496-510
35. Laskowski, M., Jr., Sealock, R. W. (1971) in The Enzymes (Boyer, P. D., ed) Vol. 3, pp. 375-473, Academic Press, Inc., New York
36. Radisky, E. S., King, D. S., Kwan, G., and Koshland, D. E., Jr. (2003) The role of the protein core in the inhibitory power of the classic serine protease inhibitor, chymotrypsin inhibitor 2. Biochemistry 42, 6484-6492 (Pubitemid 36665823)
37. Longstaff, C., Campbell, A. F., and Fersht, A. R. (1990) Recombinant chymotrypsin inhibitor 2. Expression, kinetic analysis of inhibition with α-chymotrypsin and wild-type and mutant subtilisin BPN″, and protein engineering to investigate inhibitory specificity and mechanism. Biochemistry 29, 7339-7347 (Pubitemid 20230065)
38. Huang, W., Suzuki, K., Nagase, H., Arumugam, S., Van Doren, S. R., and Brew, K. (1996) Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett. 384, 155-161 (Pubitemid 26139794)
39. Salameh, M. A., Soares, A. S., Hockla, A., and Radisky, E. S. (2008) Structural basis for accelerated cleavage of bovine pancreatic trypsin inhibitor (BPTI) by human mesotrypsin. J. Biol. Chem. 283, 4115-4123
40. Otwinowski, Z., and Minor, W. (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (Pubitemid 27085611)
41. McCoy, A. J., Grosse-Kunstleve, R. W., Storoni, L. C., and Read, R. J. (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crystallogr. 61, 458-464
42. Perrakis, A., Harkiolaki, M., Wilson, K. S., and Lamzin, V. S. (2001) ARP/ wARP and molecular replacement. Acta Crystallogr. D Biol. Crystallogr. 57, 1445-1450
43. Perrakis, A., Morris, R., and Lamzin, V. S. (1999) Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6, 458-463 (Pubitemid 29218016)
44. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (Pubitemid 27235885)
45. Emsley, P., and Cowtan, K. (2004) Coot. Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (Pubitemid 41742764)
46. Winn, M. D., Isupov, M. N., and Murshudov, G. N. (2001) Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 57, 122-133 (Pubitemid 32062682)
47. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (Pubitemid 47321791)
48. Radisky, E. S., Kwan, G., Karen Lu, C. J., and Koshland, D. E., Jr. (2004) Binding, proteolytic, and crystallographic analyses of mutations at the protease-inhibitor interface of the subtilisin BPN′/chymotrypsin inhibitor 2 complex. Biochemistry 43, 13648-13656 (Pubitemid 39431048)
49. Radisky, E. S., Lu, C. J., Kwan, G., and Koshland, D. E., Jr. (2005) Role of the intramolecular hydrogen bond network in the inhibitory power of chymotrypsin inhibitor 2. Biochemistry 44, 6823-6830 (Pubitemid 40632400)
50. Salameh, M. A., Robinson, J. L., Navaneetham, D., Sinha, D., Madden, B. J., Walsh, P. N., and Radisky, E. S. (2010) The amyloid precursor protein/ protease nexin 2 Kunitz inhibitor domain is a highly specific substrate of mesotrypsin. J. Biol. Chem. 285, 1939-1949
51. Gomis-Rüth, F. X. (2009) Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 284, 15353-15357
52. Tallant, C., Marrero, A., and Gomis-Rüth, F. X. (2010) Matrix metalloproteinases. Fold and function of their catalytic domains. Biochim. Biophys. Acta 1803, 20-28
53. Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Mangani, S., and Terni, B. (2004) Crystal structure of the catalytic domain of human matrix metalloproteinase 10. J. Mol. Biol. 336, 707-716 (Pubitemid 38183023)
54. Brew, K., Dinakarpandian, D., and Nagase, H. (2000) Tissue inhibitors of metalloproteinases. Evolution, structure, and function. Biochim. Biophys. Acta 1477, 267-283 (Pubitemid 30119906)
55. Maskos, K., and Bode,W.(2003) Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Mol. Biotechnol. 25, 241-266 (Pubitemid 37410016)
56. Fernandez-Catalan, C., Bode, W., Huber, R., Turk, D., Calvete, J. J., Lichte, A., Tschesche, H., and Maskos, K. (1998) Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J. 17, 5238-5248 (Pubitemid 28408489)
57. Iyer, S., Wei, S., Brew, K., and Acharya, K. R. (2007) Crystal structure of the catalytic domain of matrix metalloproteinase-1 in complex with the inhibitory domain of tissue inhibitor of metalloproteinase-1. J. Biol. Chem. 282, 364-371 (Pubitemid 47076625)
58. Maskos, K., Lang, R., Tschesche, H., and Bode, W. (2007) Flexibility and variability of TIMP binding. X-ray structure of the complex between collagenase- 3/MMP-13 and TIMP-2. J. Mol. Biol. 366, 1222-1231 (Pubitemid 46188638)
59. Grossman, M., Tworowski, D., Dym, O., Lee, M. H., Levy, Y., Murphy, G., and Sagi, I. (2010) The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry 49, 6184-6192
60. Gomis-Rüth, F. X., Botelho, T. O., and Bode, W. (2012) A standard orientation for metallopeptidases. Biochim. Biophys. Acta 1824, 157-163
61. Zhou, P., Tian, F., Lv, F., and Shang, Z. (2009) Geometric characteristics of hydrogen bonds involving sulfur atoms in proteins. Proteins 76, 151-163
62. Xu, D., Tsai, C. J., and Nussinov, R. (1997) Hydrogen bonds and salt bridges across protein-protein interfaces. Protein Eng. 10, 999-1012 (Pubitemid 28004646)
63. Xu, D., Lin, S. L., and Nussinov, R. (1997) Protein binding versus protein folding. The role of hydrophilic bridges in protein associations. J. Mol. Biol. 265, 68-84 (Pubitemid 27110566)
64. Sheinerman, F. B., Norel, R., and Honig, B. (2000) Electrostatic aspects of protein-protein interactions. Curr. Opin. Struct. Biol. 10, 153-159 (Pubitemid 30198940)
65. Rozas, I., Alkorta, I., and Elguero, J. (1998) Bifurcated hydrogen bonds: Three-centered interactions. J. Phys. Chem. A 102, 9925-9932 (Pubitemid 128576489)
66. Torshin, I. Y., Weber, I. T., and Harrison, R. W. (2002) Geometric criteria of hydrogen bonds in proteins and identification of "bifurcated" hydrogen bonds. Protein Eng. 15, 359-363
67. Meng, Q., Malinovskii, V., Huang, W., Hu, Y., Chung, L., Nagase, H., Bode, W., Maskos, K., and Brew, K. (1999) Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1′ residue of substrate. J. Biol. Chem. 274, 10184-10189
68. Lee, M. H., Rapti, M., and Murphy, G. (2003) Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J. Biol. Chem. 278, 40224-40230 (Pubitemid 37248590)
69. Wei, S., Chen, Y., Chung, L., Nagase, H., and Brew, K. (2003) Protein engineering of the tissue inhibitor of metalloproteinase 1 (TIMP-1) inhibitory domain. In search of selective matrix metalloproteinase inhibitors. J. Biol. Chem. 278, 9831-9834 (Pubitemid 36800485)
70. Lee, M. H., Rapti, M., Knauper, V., and Murphy, G. (2004) Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J. Biol. Chem. 279, 17562-17569 (Pubitemid 38560520)
71. Wu, B., Arumugam, S., Gao, G., Lee, G. I., Semenchenko, V., Huang, W., Brew, K., and Van Doren, S. R. (2000)NMRstructure of tissue inhibitor of metalloproteinases-1 implicates localized induced fit in recognition of matrix metalloproteinases. J. Mol. Biol. 295, 257-268 (Pubitemid 30045358)
72. Arumugam, S., Gao, G., Patton, B. L., Semenchenko, V., Brew, K., and Van Doren, S. R. (2003) Increased backbone mobility in β-barrel enhances entropy gain driving binding of N-TIMP-1 to MMP-3. J. Mol. Biol. 327, 719-734 (Pubitemid 36299074)
73. Wu, Y., Wei, S., Van Doren, S. R., and Brew, K. (2011) Entropy increases from different sources support the high affinity binding of the N-terminal inhibitory domains of tissue inhibitors of metalloproteinases to the catalytic domains of matrix metalloproteinases-1 and -3. J. Biol. Chem. 286, 16891-16899
74. Gill, S. E., and Parks, W. C. (2008) Metalloproteinases and their inhibitors. Regulators of wound healing. Int. J. Biochem. Cell Biol. 40, 1334-1347
75. Wiseman, B. S., Sternlicht, M. D., Lund, L. R., Alexander, C. M., Mott, J., Bissell, M. J., Soloway, P., Itohara, S., and Werb, Z. (2003) Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J. Cell Biol. 162, 1123-1133 (Pubitemid 37174194)
76. Kessenbrock, K., Plaks, V., and Werb, Z. (2010) Matrix metalloproteinases. Regulators of the tumor microenvironment. Cell 141, 52-67
77. Cho, N. H., Hong, K. P., Hong, S. H., Kang, S., Chung, K. Y., and Cho, S. H. (2004) MMP expression profiling in recurred stage IB lung cancer. Oncogene 23, 845-851 (Pubitemid 38241286)
78. Butler, G. S., Hutton, M., Wattam, B. A., Williamson, R. A., Knäuper, V., Willenbrock, F., and Murphy, G. (1999) The specificity of TIMP-2 for matrix metalloproteinases can be modified by single amino acid mutations. J. Biol. Chem. 274, 20391-20396
79. Williamson, R. A., Hutton, M., Vogt, G., Rapti, M., Knäuper, V., Carr, M. D., and Murphy, G. (2001) Tyrosine 36 plays a critical role in the interaction of the AB loop of tissue inhibitor of metalloproteinases-2 with matrix metalloproteinase-14. J. Biol. Chem. 276, 32966-32970
80. Lee, M. H., Verma, V., Maskos, K., Nath, D., Knäuper, V., Dodds, P., Amour, A., and Murphy, G. (2002) Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-α-converting enzyme. Biochem. J. 364, 227-234 (Pubitemid 34538966)
81. Lee, M. H., Maskos, K., Knäuper, V., Dodds, P., and Murphy, G. (2002) Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold. A new frontier in TIMP engineering. Protein Sci. 11, 2493-2503
82. Lee, M. H., Rapti, M., and Murphy, G. (2004) Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-α-converting enzyme. J. Biol. Chem. 279, 45121-45129 (Pubitemid 39430927)
83. Lee, M. H., Rapti, M., and Murphy, G. (2005) Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting. Fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}- converting enzyme. J. Biol. Chem. 280, 15967-15975 (Pubitemid 40616720)
84. Hamze, A. B., Wei, S., Bahudhanapati, H., Kota, S., Acharya, K. R., and Brew, K. (2007) Constraining specificity in the N-domain of tissue inhibitor of metalloproteinases-1. Gelatinase-selective inhibitors. Protein Sci. 16, 1905-1913 (Pubitemid 47367113)
85. Bahudhanapati, H., Zhang, Y., Sidhu, S. S., and Brew, K. (2011) Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2). Identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP- 1)). J. Biol. Chem. 286, 31761-31770
86. Lee, M. H., Atkinson, S., Rapti, M., Handsley, M., Curry, V., Edwards, D., and Murphy, G. (2010) The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment. Cancer Lett. 290, 114-122
87. Justilien, V., Regala, R. P., Tseng, I.-C, Walsh, M. P., Batra, J., Radisky, E. S., Murray, N. R., and Fields, A. P. (2012) Matrix metalloproteinase-10 is required for lung cancer stem cell maintenance, tumor initiation, and metastatic potential. PLoS One, in press